Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

被引：2

作者：

Lin, N. U. ^{[1
]}

Borges, V. F. ^{[2
]}

Patel, M. R. ^{[3
]}

Okera, M. ^{[4
]}

Meisel, J. ^{[5
]}

Wesolowski, R. ^{[6
]}

Pluard, T. ^{[7
]}

Miller, K. D. ^{[8
]}

McCarthy, N. J. ^{[9
]}

Conlin, A. K. ^{[10
]}

Mahtani, R. ^{[11
]}

Sabanathan, D. ^{[12
]}

McCann, K. E. ^{[13
]}

Roesch, E. ^{[14
]}

Mathauda-Sahota, G. ^{[15
]}

Schroeder, J. ^{[16
]}

Hamilton, E. P. ^{[17
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Univ Colorado, Med Oncol, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA

[3] Sarah Cannon Res Inst, Drug Dev, Florida Canc Specialists, Ft Myers, FL USA

[4] Canc Res SA, Oncol Dept, Adelaide, SA, Australia

[5] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA USA

[6] Ohio State Univ, Div Med Oncol, Ctr Comprehens Canc, Columbus, OH USA

[7] St Lukes Hlth Syst, Dept Med Oncol, St Lukes Hosp Kansas City, Kansas City, MO USA

[8] Indiana Univ, Hematol & Oncol Dept, Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA

[9] Wesley Med Ctr, Med Oncol, ICON Canc Ctr, Auchenflower, Qld, Australia

[10] Providence Canc Inst, Med Oncol, Portland, OR USA

[11] Baptist Hlth South Florida, Dept Med Oncol, Miami Canc Inst, Miami, FL USA

[12] Macquarie Univ, Dept Clin Med, Macquarie Pk, NSW, Australia

[13] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med, Los Angeles, CA USA

[14] Cleveland Clin, Taussig Canc Ctr, Med Oncol, Cleveland, OH USA

[15] Olema Pharmaceut Inc, Clin Sci, San Francisco, CA USA

[16] Olema Pharmaceut Inc, Biostat, San Francisco, CA USA

[17] Tennessee Oncol, Drug Dev Unit, Sarah Cannon Res Inst, Nashville, TN USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.559

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

382MO

引用

页码：S338 / S338

页数：1